Adeno‑Associated Virus (AAV) Gene Therapy refers to the use of engineered AAV vectors to deliver therapeutic genetic material into patient cells, offering a platform for treating inherited, oncologic, and rare diseases. Its clinical relevance stems from AAV’s low immunogenicity and long‑term transgene expression, positioning it as a cornerstone of next‑generation precision medicines. The Adeno‑Associated Virus (AAV) Gene Therapy market size was estimated at approximately $3.6 billion in 2025, and analysts project a robust growth outlook with a compound annual growth rate (CAGR) of roughly 22% through 2033, driven by expanding indications, favorable regulatory pathways, and escalating venture capital investment. Primary macro‑drivers include accelerating approvals of AAV‑based products, breakthroughs in capsid engineering, and growing reimbursement frameworks. The market is shaped by three pivotal forces: rapid technology shifts toward next‑generation capsids, increasingly stringent but supportive regulatory landscapes, and intensifying competitive dynamics among biotech innovators and large‑pharma partners. North America remains the largest market by revenue, while the Asia‑Pacific region is emerging as the fastest‑growing segment, propelled by rising biotech ecosystems and government incentives.